Lapc 4

Manufactured by Merck Group

The LAPC-4 is a laboratory equipment product designed for specific applications. It serves as a tool for researchers and scientists, enabling them to conduct various experiments and analyses. The core function of the LAPC-4 is to provide a controlled and reliable platform for their work, but further details on its intended use are not available.

Automatically generated - may contain errors

Lab products found in correlation

Lncap, by Merck Group (3 mentions) Du145, by American Type Culture Collection (2 mentions) D glucose, by Merck Group (1 mentions) Lncap, by American Type Culture Collection (1 mentions) Docetaxel, by Merck Group (1 mentions) Fetal calf serum (fcs), by PAN Biotech (1 mentions) Dihydrotestosterone, by Merck Group (1 mentions) Glutamax, by Lonza (1 mentions) Du145, by PAN Biotech (1 mentions) Du145, by Merck Group (1 mentions) Na pyruvate, by Lonza (1 mentions) Rpmi 1640, by PAN Biotech (1 mentions) Fetal bovine serum (fbs), by Quality Biological (1 mentions) Sodium orthovanadate, by Merck Group (1 mentions) Pcr mycoplasma detection set, by Takara Bio (1 mentions) Azd1480, by MedChemExpress (1 mentions) Neomycin, by Merck Group (1 mentions)

3 protocols using lapc 4

Prostate Cancer Cell Line Cultivation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human cell lines PC3, DU145, and LNCaP were obtained from American Type Culture Collection (ATCC, Rockville, MD). LAPC4 were a kind gift from Prof. A. Cato (Institute of Toxicology and Genetics, Karlsruher Institut für Technologie, Germany). Docetaxel‐resistant PC3‐DR and DU145‐DR were previously established by Puhr et al.14 All cells were cultured in Roswell Park Memorial Institute 1640 (RPMI‐1640) (PAN Biotech, Aidenbach, Germany) containing 10% (v/v) fetal calf serum (PAN Biotech), 1% (v/v) penicillin/streptomycin and 1% (v/v) GlutaMAX (both from Lonza, Vienna, Austria). LNCaP were supplemented with 1% (v/v) 4‐(2‐hydroxyethyl)‐1‐piperazineethanesulfonic acid (HEPES) (Sigma, Vienna), 1% (v/v) d‐glucose (Sigma), 1% (v/v) Na‐pyruvate (Lonza) and LAPC4 with 100 nmol/L dihydrotestosterone (Sigma). PC3‐DR and DU145‐DR were cultured in the presence of 12.5 nmol/L Docetaxel (Sigma). The authenticity of all cell lines was validated via short tandem repeat profiling.

Gruber M., Handle F, & Culig Z. (2019). The stem cell inhibitor salinomycin decreases colony formation potential and tumor‐initiating population in docetaxel‐sensitive and docetaxel‐resistant prostate cancer cells. The Prostate, 80(3), 267-273.

+ Open protocol

+ Expand

Prostate Cancer Cell Line Cultivation

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human PC cell lines LNCap, PC-3, DU145 (from ATCC) and CWR22Pc (42 (link)) were cultured in RPMI 1640 growth media (Mediatech) containing 10% fetal bovine serum (FBS; Quality Biological) and penicillin/streptomycin (50 IU/ml and 50 μg/ml, respectively; Mediatech). LAPC-4 cells (from Dr. Charles Sawyers, Sloan-Kettering Memorial Cancer Center, NY) were cultured under the same conditions, with substitution of RPMI 1640 for IMDM (Mediatech). LNCap, LAPC-4 and CWR22Pc cells were cultured in the presence of (DHT) (Sigma-Aldrich) (LNCap: 0.5 nM, LAPC-4: 1 nM, CWR22Pc: 0.8 nM). CWR22Pc subline expressing AR-F876L (from Dr. Charles Sawyers, Sloan-Kettering Memorial Cancer Center) was cultured in RPMI 1640 supplemented with ENZ (10 μM). All cell lines were regularly authenticated by observation of cell morphology, androgen-responsiveness and expression of cell line specific markers and tested for mycoplasma contamination (PCR Mycoplasma Detection Set; Takara Bio Inc.,) every 3 months. ENZ and AZD1480 were purchased from MedChem Express, MG132 and cyclohexamide (CHX) from Calbiochem, LFA102 (43 (link)) from Novartis, sodium orthovanadate from Sigma-Aldrich and IST5-002 was provided by Fox Chase Chemical Diversity Center. Recombinant human prolactin (Prl) was obtained from NIDDK Hormone and Peptide Program, Torrance, CA.

Udhane V., Maranto C., Hoang D.T., Gu L., Erickson A., Devi S., Talati P.G., Banerjee A., Iczkowski K.A., Jacobsohn K., See W.A., Mirtti T., Kilari D, & Nevalainen M.T. (2019). Enzalutamide Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors. Molecular cancer therapeutics, 19(1), 231-246.

+ Open protocol

+ Expand

Stable UGT2B28 Knockdown in Prostate Cancer Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

To generate a stable knockdown of UGT2B28 in LNCaP, LAPC-4, and VCaP cells, cells were transduced with two independent clones of lentiviral UGT2B28 shRNA (Clone ID: V3LHS_378777) and non-targeting control pGIPZ shRNA purchased from the Cell-Based Assay Screening Service Core (Baylor College of Medicine). Transduction was carried out at an MOI of 5, and cells containing the KD were stably selected with 1 µg/mL (LNCaP, LAPC-4), and 2 µg/mL (VCaP) puromycin from Sigma Aldrich (Cat. #P8833) in their respective media. Similarly, stable overexpression of UGT2B28 in NT and KD cells (NTOE, KD2OE, and KD4OE) was achieved using over-expression lentiviral vector for UGT2B28 (LPP-H0607-Lv157-050) along with a negative control (LPP-NEG-Lv157-050) purchased from Genecopoeia at an MOI of 5 and the overexpressing cells were stably selected using neomycin from Sigma Aldrich (1 mg/mL).

Ravindran A., Krieger K.L., Kaushik A.K., Hovington H., Mehdi S., Piyarathna D.W., Putluri V., Basil P., Rasaily U., Gu F., Dang T., Choi J.M., Sonavane R., Jung S.Y., Wang L., Mehra R., Weigel N.L., Putluri N., Rowley D.R., Palapattu G.S., Guillemette C., Lacombe L., Lévesque É, & Sreekumar A. (2022). Uridine Diphosphate Glucuronosyl Transferase 2B28 (UGT2B28) Promotes Tumor Progression and Is Elevated in African American Prostate Cancer Patients. Cells, 11(15), 2329.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!